Prior to treatment, the levels of carcinoembryonic antigen (CEA) and carbohydrate antigen 19 − 9 (CA19-9), which are tumor markers, were 2.1 ng/mL and 7 U/mL, respectively. This evidence concerns the gene CEACAM5 and neoplasm.